Visceral leishmaniasis vaccine - IDRI

Drug Profile

Visceral leishmaniasis vaccine - IDRI

Alternative Names: LEISH-F3 + GLA-SE

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Bill & Melinda Gates Foundation; Infectious Disease Research Institute
  • Developer Gennova Biopharmaceuticals; Infectious Disease Research Institute; Zydus Cadila
  • Class Leishmaniasis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Visceral leishmaniasis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Visceral-leishmaniasis in India (IM, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Visceral-leishmaniasis(In volunteers) in USA (IM, Injection)
  • 01 Apr 2014 Infectious Disease Research Institute initiates enrolment in a phase I trial for Visceral leishmaniasis (prevention) in USA (NCT02071758)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top